Burixafor (TG-0054) is a new, potent and selective chemokine receptor antagonist discovered by TaiGen. Around 15 patients will be enrolled in this open-label trial, which is designed to
I-STAR technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BVGH,
Scheduled to be completed by January 2017, the new facility is claimed to be the largest mammalian cell culture manufacturing facility using disposable bioreactors in the world. The
The joint research is funded by a grant from CurePSP, a nonprofit organization, which will support the collection and analysis of exome sequencing data from more than 700
Discovered and developed by Lycera based on technology licensed from the University of Michigan, LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing
The AR-12 orphan drug status was based on application packages that included relevant data from pre-clinical models for each condition. In the application regarding cryptococcosis, results of an
Breo is a fixed-dose combination of fluticasone furoate (FF) and vilanterol (VI) and two strengths, 100/25mcg and 200/25mcg of the combination have been approved in the US for
Xilonix is designed to block chronic inflammation associated with malignant tumor growth. The US Phase III trial was initially launched in March 2013 and patients were enrolled at
Opdivo is a programed death-1 (PD-1) immune checkpoint inhibitor that has received approval from the FDA as a monotherapy in two cancer indications. The sBLA is based on
Kybella is a cytolytic drug, which when injected into the fat under the chin destroys the cell membrane. When injected into submental fat, the drug works by destroying
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.